CCL2 and cardiomyopathy: Only one of the identified studies assessed the effect of nanoceria (7 nm, 0.15 mM in a 100 μL solution) administered intravenously twice a week for 2 weeks in a model of cardiomyopathy in transgenic mice with cardiac-specific expression of MCP-1 [116].